Physician

Michael Casimir Danielski, M.D.

According to 2025 Medicare claims, Michael Danielski, M.D. (NPI: 1114918984) practices internal medicine in the Rockingham County-Strafford County, NH market, with the plurality of this provider's patient population coming from Strafford, NH. This provider's primary affiliated billing organization is SEACOAST KIDNEY & HYPERTENSION SPECIALISTS, P.L.L.C. (NPI: 1780877902; TIN: 260697394) and primary practice location at 03878-4300. Danielski is affiliated with the MaineHealth Accountable Care Organization (ACO ID: A1290), participating under the MSSP model.

Danielski's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 523 traditional Medicare patients, billed 1,874 HCPCS/CPT codes, and received $240,115 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 856 prescription claims across 168 beneficiaries totaling $138,559 in drug costs, led by Calcitriol (Calcitriol). DME data shows 48 claims. Open Payments data shows 1 records totaling $77. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs started with an early spike, then settled into a lower baseline, moving from $238,580 to $138,559. In contrast, DME billing represents a smaller volume and changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	711	2,753	$266,570
2016	740	2,473	$261,159
2017	716	2,528	$270,428
2018	708	2,348	$255,065
2019	660	2,390	$254,745
2020	601	1,953	$242,670
2021	633	2,453	$301,801
2022	561	2,066	$250,989
2023	573	2,104	$253,472
2024	523	1,874	$240,115

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	180	999	$238,580
2016	206	1,110	$195,661
2017	198	1,067	$143,550
2018	193	1,195	$78,853
2019	216	1,204	$131,465
2020	203	1,020	$80,962
2021	205	1,051	$94,101
2022	212	1,109	$68,602
2023	201	973	$52,474
2024	168	856	$138,559

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	136	$5,822
2016	N/R	73	$2,418
2017	N/R	104	$2,529
2018	N/R	102	$3,766
2019	N/R	72	$1,930
2020	N/R	91	$2,886
2021	N/R	52	$1,294
2022	N/R	12	$119
2023	N/R	28	$1,629
2024	N/R	48	$1,505

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	98	414	$272
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	107	130	$133
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	57	87	$93
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	209	382	$90
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	165	458	$61

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Calcitriol	Calcitriol	188	15,140	$4,450
Amlodipine Besylate	Amlodipine Besylate	88	6,957	$606
Chlorthalidone	Chlorthalidone	31	2,400	$601
Losartan Potassium	Losartan Potassium	71	5,438	$576
Metoprolol Succinate	Metoprolol Succinate	35	2,860	$512

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7520	Sirolimus, oral, 1 mg	N	N/R	24	$1,204
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	11	$207
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	13	$94

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$77	CALLIDITAS THERAPEUTICS US INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Michael Casimir Danielski, M.D.?

Tedicare shows public-source Medicare data for Michael Casimir Danielski, M.D. (NPI 1114918984), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Michael Casimir Danielski, M.D. have ACO affiliation data?

Michael Casimir Danielski, M.D. is shown with ACO affiliation data for MaineHealth Accountable Care Organization (MSSP, ACO ID A1290).

What billing organization is linked to Michael Casimir Danielski, M.D.?

Michael Casimir Danielski, M.D. is linked to SEACOAST KIDNEY & HYPERTENSION SPECIALISTS, P.L.L.C. (billing NPI 1780877902) in the available physician profile data.

Does Michael Casimir Danielski, M.D. have Open Payments data?

Michael Casimir Danielski, M.D. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.